RxDoctor Payments Data

Timothy Ducey, MD

Ophthalmology · Warner Robins, GANPI 1780023960

Payments from drug & device makers

$1,734in general payments, 2019–2025

Across 50 payments — averaging $34.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$304
  • Bausch & Lomb Americas Inc.$298
  • AbbVie$294
  • Astellas Pharma US Inc$125
  • Glaukos Corporation$116
  • Tarsus Pharmaceuticals, Inc.$97
  • plus $500 from 9 others

What the payments were for

  • Food & beverage$1,71699%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,734 in reported general payments places this provider in the 45th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$420,571
Medicare patients
1,138
Services billed
3,249

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine92$97,732
IlevroNepafenac238$90,094
LumiganBimatoprost149$64,475
XiidraLifitegrast21$27,805
Prednisolone Acetate576$20,454
RocklatanNetarsudil Mesylat/Latanoprost45$19,340
ProlensaBromfenac Sodium51$17,713
Bromfenac Sodium129$15,943
RhopressaNetarsudil Mesylate42$15,180
CombiganBrimonidine Tartrate/Timolol53$11,886
Alphagan PBrimonidine Tartrate46$10,519
CequaCyclosporine11$8,275
Cyclosporine25$8,228
Ofloxacin449$5,823
SimbrinzaBrinzolamide/Brimonidine Tart23$5,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$294$184,613340 claims
Bausch & Lomb Americas Inc.Xiidra$298$27,80521 claims
Sun Pharmaceutical Industries Inc.Cequa$69$8,27511 claims
AlconSimbrinza$304$5,05323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Warner Robins

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →